Federal Food and Drug Administration] about depression and suicidal ideation associated with semaglutide, as it suggests that these concerns may not be directly linked to these specific weight-loss treatments. In early January 2024, the FDA released an update regarding their investigation of Our preliminary evaluation has not found evidence that use of these medicines causes suicidal thoughts or actions, the agency concluded
Your box of happiness will be delivered in 3-5 business days
Patients can prepare by being proactive: reviewing and adjusting insurance coverage, asking providers about alternatives, using discount programs, and stocking up when possible
Trends in lifetime risk and years of life lost due to diabetes in the USA, 19852011: a modelling study
Cardiovascular outcomes data for Ozempic comes from the SELECT trial, which demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with established heart disease but without diabetes